Back to Search
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
Hollywood, Florida, 33024
Savannah, Georgia, 31406
Sioux City, Iowa, 51106
Lenexa, Kansas, 66219
Worcester, Massachusetts, 01655
Savannah, Georgia, 31406
Sioux City, Iowa, 51106
Lenexa, Kansas, 66219
Worcester, Massachusetts, 01655
Search ended 06/24/2023
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
| Ages Eligible for Study | Min Age: 18 Years - Max Age: 30 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Pelham, Alabama and more
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Cytomegalovirus Infection Read more
Tuscaloosa, Alabama and more
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury
Neurobehavioral Disinhibition Read more
Palo Alto, California and more